中国普通外科杂志2026，Vol.35Issue(2)：223-229,7.DOI:10.7659/j.issn.1005-6947.260042
外科视角下《WHO成人肥胖GLP-1药物应用与适应证指南》解读:机遇、挑战与中国临床路径思考
Interpretation of the World Health Organization guideline on the use and indications of GLP-1 therapies for the treatment of obesity in adults from a surgical perspective:opportunities,challenges,and implications for clinical pathways in China
摘要
Abstract
The recent release of the World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults further establishes the role of GLP-1 receptor agonists in obesity management.From a surgical perspective,this article systematically interprets the key recommendations of the guideline,with a focus on the impact of GLP-1-based therapies on the current treatment paradigm and their implications for bariatric and metabolic surgery.In addition,the potential clinical pathways for integrating pharmacological and surgical approaches in China are discussed,aiming to provide insights for optimizing comprehensive obesity management.关键词
肥胖症/胰高血糖素样肽-1受体激动剂/减肥手术/解读Key words
Obesity/Glucagon-Like Peptide-1 Receptor Agonists/Bariatric Surgery/Interpretation分类
医药卫生引用本文复制引用
刘晨鸣,张鹏..外科视角下《WHO成人肥胖GLP-1药物应用与适应证指南》解读:机遇、挑战与中国临床路径思考[J].中国普通外科杂志,2026,35(2):223-229,7.基金项目
国家重点研发计划资助项目(2022YFC2505204) （2022YFC2505204）
四大慢病重大专项基金资助项目(2025ZD0550503). （2025ZD0550503）
